Market Overview

UPDATE: Credit Suisse Initiates Coverage On Lombard Medical On Positive Outlook For Aorfix


In a report published Monday, Credit Suisse analyst Matthew Keeler initiated coverage on Lombard Medical (NASDAQ: EVAR) with an Outperform rating and $10.50 price target.

In the report, Credit Suisse noted, “Lombard is a relatively new entrant in the $1.2B WW endovascular aneurysm repair (EVAR) market. While the EVAR market is competitive and well penetrated (we forecast 5% market growth going forward), we believe Lombard's Aorfix device is differentiated enough (as described below) to take share from larger competitors. We project Aorfix reaching ~6% share of the WW AAA market sales by 2020.”

Lombard Medical closed on Friday at $7.00.

Latest Ratings for EVAR

Aug 2016MaintainsEqual-Weight
Nov 2015DowngradesOverweightEqual-Weight
Nov 2015DowngradesBuyNeutral

View More Analyst Ratings for EVAR
View the Latest Analyst Ratings

Posted-In: Credit Suisse Matthew KeelerAnalyst Color Initiation Analyst Ratings


Related Articles (EVAR)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Credit Suisse Raises Q2 Imbruvica Sales Forecast For Pharmacyclics

Edwards Receives FDA Clearance For Advanced Noninvasive Monitoring System